Evaxion A (EVAX) Return on Equity (2023)

Evaxion A (EVAX) reported Return on Equity of 0.06% for Q2 2023, down 56.49% quarter-over-quarter from 0.04% in Q1 2023.

Evaxion A (EVAX) Return on Equity (2023) Analysis & Trends

Evaxion A has reported Return on Equity for 1 years, with the latest figure at 0.06% in Q2 2023.

For the quarter ending Q2 2023, Return on Equity changed N/A year-over-year to 0.06%; the trailing twelve-month figure through Jun 2023 stood at 0.06% (changed N/A YoY), and the FY2025 full-year result was 0.01%, down 5.0% from the prior year.
Return on Equity for Q2 2023 stood at 0.06%, down from 0.04% in the prior quarter.
The five-year high for Return on Equity was 0.04% in Q1 2023, with the low at 0.06% in Q2 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROE (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-0.81%
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-0.04%
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.00%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-0.01%
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	0.00%
9	Abivax	90.15 Bn	90.15 Bn	-	-0.01%
10	Regeneron Pharmaceuticals	63.59 Bn	54.83 Bn	3.31 Bn	0.00%

Historic Data

Download Data

Date	Value
Jun 30, 2023	-0.06%
Mar 31, 2023	-0.04%